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Diabetic nephropathy is the major cause of end-stage renal
disease worldwide. Although the renin–angiotensin system
has been implicated in the pathogenesis of diabetic
nephropathy, angiotensin I-converting enzyme inhibitors
have a beneficial effect on diabetic nephropathy
independently of their effects on blood pressure and plasma
angiotensin II levels. This suggests that the kallikrein–kinin
system (KKS) is also involved in the disease. To study the role
of the KKS in diabetic nephropathy, mice lacking either the
bradykinin B1 receptor (B1R) or the bradykinin B2 receptor
(B2R) have been commonly used. However, because absence
of either receptor causes enhanced expression of the other,
it is difficult to determine the precise functions of each
receptor. This difficulty has recently been overcome by
comparing mice lacking both receptors with mice lacking
each receptor. Deletion of both B1R and B2R reduces nitric
oxide (NO) production and aggravates renal diabetic
phenotypes, relevant to either lack of B1R or B2R,
demonstrating that both B1R and B2R exert protective effects
on diabetic nephropathy presumably via NO. Here, we review
previous epidemiological and experimental studies, and
discuss novel insights regarding the therapeutic implications
of the importance of the KKS in averting diabetic
nephropathy.
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BENEFICIAL EFFECTS OF GENETICALLY DECREASED ACE
LEVELS ON DIABETIC NEPHROPATHY
Angiotensin I-converting enzyme (ACE), a zinc metallopep-
tidase widely distributed on the surface of endothelial and
epithelial cells, plays a key role in the renin–angiotensin
system and in the kallikrein–kinin system (KKS). It catalyzes
not only the conversion of angiotensin I to the vasoconstrict-
ing peptide angiotensin II, but also the conversion of active
bradykinin, kallidin, and kallidin-like peptide to inactive
bradykinin (1–7), kallidin (1–8), and kallidin-like peptide
(1–8), respectively1,2 (Figure 1). Since ACE has a 30 times
lower Km and 10 times higher kcat/Km, it has higher affinity
and efficiency for kinins than for angiotensin I,3 and it is
responsible for B47% of the total plasma kininase activity.4
Furthermore, computer simulations show that modest changes
in ACE levels affect the levels of its substrates much
more than the levels of its products, indicating that relatively
small changes in ACE activity affect kinin levels more than
angiotensin II levels.5,6 Indeed, an ACE inhibitor, perindopril,
significantly increases plasma levels of bradykinin at doses
much lower than those required to reduce angiotensin II
levels.7
A common 287-bp insertion/deletion (I/D) polymor-
phism in intron 16 of the ACE gene occurs in humans.
Importantly, the two alleles (I and D) are associated with
different plasma ACE levels. The D/D and I/D genotypes
show higher plasma levels of ACE than the I/I genotype by 65
and 30%, respectively.8 However, the ACE polymorphism
does not significantly affect blood pressure, plasma angio-
tensin II, or aldosterone levels.9 Nevertheless, the I and D
human ACE alleles are associated with different risks for
developing diabetic complications, including nephropa-
thy,10,11 neuropathy,12 retinopathy,13 myocardial infarction,14
and stroke.15 In all these diabetes-associated conditions, the
D allele associated with higher levels of ACE confers the
increased risk. The ACE I/D polymorphism also affects
bradykinin metabolism in humans.16 Degradation of brady-
kinin through the ACE pathway in normotensive volunteers
was greatest in the D/D genotype, intermediate in the I/D
genotype, and least in the I/I genotype, as measured by the
ratio of bradykinin (1–5) (inactive stable metabolite of
bradykinin) to bradykinin.16 Moreover, the ratio of brady-
kinin (1–5) to bradykinin positively correlated with plasma
ACE activity. A recent report has further demonstrated that
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the D/D genotype in normotensive Brazilian male subjects
has higher levels of plasma kallikrein activity than I/D and I/I
genotypes by 30 and 60%, respectively, indicating possible
compensation for the increased bradykinin degradation that
occurs in the D/D genotype.17 Plasma ACE activity is also
higher in the D/D genotype of this population. Taken
together, these studies in humans demonstrate that the D
allele is associated with not only enhanced plasma ACE
activity, but also increased degradation of plasma bradykinin.
In genetically engineered mice having one, two, or three
functional copies of the ACE gene at its normal chromosomal
location, plasma ACE activities are 62% of normal in the
one-copy animals, 100% in the two-copy animals (wild-
type), and 144% in the three-copy animals.18 Thus, these
mouse models were originally expected to show different
levels of blood pressures. However, the copy number of the
ACE gene had no effect on blood pressure, an observation that
supports the human polymorphism studies. Later work with
the same series of mice suggests that quantitative changes
in expression of the ACE gene may measurably affect blood
pressures when accompanied by additional genetic or
environmental factors that stress the homeostatic machinery.
This was demonstrated by an experiment in which diabetes
was induced with streptozotocin (STZ) treatment in mice
having one, two, and three copies of the ACE gene.19 After
12 weeks, the blood pressures of the one-copy mice and the
wild-type (two-copy) mice were not affected by induction of
diabetes. However, the blood pressure of the three-copy
diabetic mice increased with time, and 12 weeks later were
10–20 mm Hg higher than those of the one- and two-copy
diabetic mice. Also, the three-copy diabetic mice had overt
proteinuria 12 weeks after induction of diabetes, whereas the
one- and two-copy diabetic mice progressed much less
rapidly. Importantly, proteinuria was significantly correlated
with plasma ACE levels in the three-copy diabetic mice.
Furthermore, urinary kallikrein significantly increased with
increase in ACE copy number and tended to increase with
diabetes, again implying the existence of possible compensa-
tion for increased bradykinin degradation.
Thus, a modest genetic increase in ACE levels is sufficient
to aggravate nephropathy in diabetes, partly through
increased bradykinin degradation.
ROLE OF THE KKS IN THE BENEFICIAL EFFECT OF ACE
INHIBITORS ON DIABETIC NEPHROPATHY
Several clinical studies have shown the beneficial effects of
ACE inhibitors on diabetic nephropathy in patients with
Type 120 or Type 2 diabetes.21 The Collaborative Study
demonstrated that an ACE inhibitor, captopril, reduces the
risk of the combined end point of death, dialysis, and
transplantation by 50% compared with placebo in patients
with Type 1 diabetes.20 Importantly, this beneficial effect of
captopril is independent of blood pressure. The Bergamo
Nephrologic Diabetes Complications Trial (BENEDICT)
demonstrated that another ACE inhibitor, trandolapril,
reduces the onset of microalbuminuria by 40–50% compared
to placebo or the calcium-channel blocker verapamil in
patients with hypertension, Type 2 diabetes, and normal
urinary albumin excretion.21 The reduced incidence of
microalbuminuria is still significant even after adjustment
for blood pressure. These clinical data provide convincing
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Figure 1 | The kallikrein–kinin system (KKS) components and
protective effects of the KKS on diabetic nephropathy. The
kinins, bradykinin and kallidin in humans or bradykinin and the
kallidin-like peptide (KLP) in rodents, are generated from
kininogens by kallikreins. All the kinins are strong agonists of the
bradykinin 2 receptor (B2R), and less so of the bradykinin B1
receptor (B1R). Kininase I removes arginine from the carboxyl
terminus of the kinins and generates their des-Arg derivatives,
which are agonists mainly of B1R. Kininase II (ACE, angiotensin I-
converting enzyme), neprilysin (NEP, endopeptidase 24.11), and
endothelin-converting enzyme (ECE) all remove two amino acids
(Phe and Arg) from the carboxyl terminus of the kinins, and
inactivate them. Red and blue indicate active kinins and inactive
kinins, respectively. The thickness of arrows arising from the kinins
indicates the relative potency of each peptide to elevate
intracellular calcium concentrations. Binding of the active kinins
to both bradykinin receptors stimulates at least two intracellular
signaling pathways, phospholipase A2 (PLA2)-dependent and
phosphatidylinositol-specific phospholipase C (PI-PLC)-dependent
pathways. The activated signaling pathways lead to the
production of nitric oxide (NO) and prostaglandins (PGs), which
exert protective effects on diabetic nephropathy. Gi, Gi protein;
Gq, Gq protein. Adapted from Kakoki et al.2
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evidence that ACE inhibitors have blood pressure–indepen-
dent beneficial effects on the diabetic nephropathy in both
Type 1 and Type 2 diabetes.22
Beneficial effects of angiotensin II type 1 receptor blockers
(ARB) on diabetic nephropathy have also been reported. The
RENAAL (Reduction of Endpoints in NIDDM with the
Angiotensin II Antagonist Losartan) study demonstrated that
an ARB, losartan, reduced the risk of the primary end point,
which was the composite of a doubling of the baseline serum
creatinine concentration, end-stage renal disease, or death
from any cause, by 16% compared with placebo in patients
with Type 2 diabetes.23 The Irbesartan study also demon-
strated that an another ARB, irbesartan, reduced the risk of
the primary end point, which was the same as the RENAAL
study, by 20% or 23% compared with placebo or with
calcium-channel blocker amlodipine, respectively, in patients
with Type 2 diabetes.24 The beneficial effects of an ARB in
both studies remain significant after adjustment for blood
pressure.
In addition to the well-established protective role of
angiotensin II blockade in systemic and intrarenal renin–
angiotensin system,25–29 stimulation of the KKS partly explains
the beneficial effects of ACE inhibitors and ARBs that occur
independent of blood pressure in diabetic nephropathy. ACE
inhibitors increase the plasma levels of bradykinin by
inhibiting its degradation in rats and in humans.7,30,31 Also,
ACE inhibition has been shown to be protective against
diabetic nephropathy via the KKS in many animal models.
The beneficial effects of ACE inhibitors are attenuated by
a bradykinin B2 receptor (B2R) antagonist in STZ-treated
rat,32,33 in obese Zucker diabetic fatty rats,34 and in C57BLKS
db/db mice.35 These experiments strongly suggest that the
protective effects of ACE inhibitors are partly mediated by
B2R signaling.
ARBs increase plasma bradykinin levels by twofold in
hypertensive humans, possibly due to reduction in pulmo-
nary ACE and neutral endopeptidase activities.36 This implies
that the beneficial effects of ARB are partly mediated by the
KKS via the activation of angiotensin II type 2 receptors.37–41
Angiotensin II stimulates angiotensin II type 2 receptors in
vascular smooth muscle cells treated with an ARB. This
stimulation leads to intracellular acidosis, mediated by
inhibition of amiloride-sensitive Naþ /Hþ exchanger activ-
ity, resulting in the enhancement of kininogenase activity,
which increases bradykinin release.41
These observations in humans and animals emphasize the
important role of the KKS in the beneficial effects on diabetic
nephropathy of treatment with ACE inhibitors or ARB.
ARE PATIENTS WITH THE ACE D ALLELE MORE RESPONSIVE
TO ACE INHIBITORS?
Numerous studies indicate that the I/I genotype of the ACE
polymorphism has a protective effect on the development
of diabetic nephropathy, whereas the D/D genotype confers
an increased risk.10,11 Therefore, it might be expected that
diabetic patients having the D allele would have a greater
response to treatment with ACE inhibitors than those having
the I allele manifested as a greater reduction in micro-
albuminuria or other renal end point. However, as reviewed
by Ruggenenti et al.,42 it is uncertain whether the ACE
polymorphism affects the therapeutic benefits of ACE
inhibitor treatment. Thus, the EUCLID trial shows that
lisinopril, an ACE inhibitor, reduced albuminuria in Type 1
diabetic patients compared with placebo by 51.5% in the I/I
genotype, 14.8% in the I/D genotype, and 7.7% in the D/D
genotype, indicating that patients with the I allele have more
favorable response to ACE inhibitor than those with the D
allele.43 Other studies in Type 1 diabetic patients treated with
ACE inhibitors also show that the I allele is associated with
better renal outcomes compared with the D allele.44,45 In
addition, a study of Chinese Type 2 diabetic patients treated
with an ACE inhibitor demonstrates that the I/I and I/D
genotypes are associated with reduced risk of mortality and
occurrence of composite renal end point, but not the D/D
genotype.46 In contrast to treatment with ACE inhibitors, the
RENAAL study demonstrated that losartan, an ARB, has a
reduced risk of the primary end points compared with
placebo by 5.8% in the I/I genotype, 17.6% in the I/D
genotype, and 27.9% in the D/D genotype, indicating the
greatest renoprotective response to ARB treatment in the D/D
genotype.47 Although no reasonable explanations regarding
the conflicting results associated with ACE polymorphism
have been published, selection bias of the patients and several
confounding factors, such as changes in antihypertensive
drugs, blood pressure, and blood glucose levels, all can
influence the clinical outcome of the study. Further studies
are warranted.
KININ RECEPTORS IN DIABETIC NEPHROPATHY
Kinins are potent renal vasodilators, and exhibit antithrom-
botic and antifibrotic activities. The kinins exert their
biological effects through the activation of G-protein-coupled
receptors with seven transmembrane domains, designated B1
and B2 receptors (B1R and B2R).48,49 B2R is constitutively
expressed in most tissues, including all segments of the
kidney, and it mediates the majority of the physiological
effects of kinins in health. In contrast, B1R is expressed at
only low levels under physiological conditions, but its
expression is induced by various pathological stimuli, such
as ischemia/reperfusion injury,50 proinflammatory cyto-
kines,51,52 diabetes,53 bacterial endotoxins,54 and angiotensin
II,55 implying an important role of B1R activation under
pathological situations. The cytokine-induced upregulation
of B1R is mainly regulated by mitogen-activated protein
kinase and nuclear factor-kB.51,56,57 Indeed, a nuclear factor-
kB binding site is detected in the promoter region of human
B1R gene.51,58
It is well documented that expression of the B1R and B2R
compensates each other under a variety of conditions
(Table 1). Expression of B1R in the kidney and heart is
enhanced in B2R-null mice.59,60 Similarly, B2R gene expres-
sion is enhanced in the same tissues in B1R-null mice.61,62
Kidney International (2012) 81, 733–744 735
H Tomita et al.: Kinins and diabetic nephropathy rev iew
Thus, absence of one bradykinin receptor may be compen-
sated by overexpression of the remaining receptor. Such a
compensative gene expression pattern of both receptors
makes it difficult to elucidate pathological function and role
of each receptor in diseases. In support of this mutual
compensation, mice lacking both B1R and B2R show a
reduced inflammatory response in a capsaicin-induced
cutaneous neurogenic inflammation model, whereas the
response is normal in mice lacking either B1R or B2R alone.63
The expression levels of both B1R and B2R in the diabetic
kidney are enhanced in STZ-treated C57BL/6J mice64 and
rats,65,66 and in Akita diabetic mice,59 which are a Type 1
diabetic animal model having a C96Y dominant-negative
mutation in the Insulin 2 (Ins2) gene.67 This upregulation of
both receptors may be due to a direct effect of hyperglycemia,
as suggested by in vitro experiments using rat endothelial
cells and vascular smooth muscle cells.68,69 Bradykinin levels
but not angiotensin II levels are also increased in both the
plasma and kidney of STZ-treated rats, when compared
with non-STZ-treated rats.27 In humans, although no
differences are seen in circulating levels of bradykinin and
kallidin peptides between Type 2 diabetic patients and
non-diabetic patients, plasma levels of tissue kallikrein,
which is a serine protease that converts kininogen to the
active bradykinin, are increased by 62% in diabetic
patients.70 The plasma angiotensin II levels are not different
between those patient groups. These findings suggest that the
KKS plays a more significant role in the pathogenesis of
diabetes and diabetic nephropathy than the renin–angioten-
sin system.
We have recently reported that loss of B2R in 6-month-old
male Akita diabetic mice (B2R-null-Akita) exacerbates many
of the renal diabetic phenotypes, including albuminuria
(fourfold increase compared to Akita mice alone), interstitial
fibrosis, and glomerular basement membrane (GBM) thick-
ening59 and induces premature aging.71 The mice also have a
substantial increase in B1R gene expression in the kidney, but
this does not protect them from developing diabetic
nephropathy. In contrast, Tan et al.72 have reported that
deletion of B2R is protective against albuminuria and
increased glomerular mesangial area that develop in diabetic
nephropathy induced by STZ. These conflicting results may
be due to differences in the strains and ages of the mice used,
in the method of induction of diabetes, and in the severity of
hyperglycemia, as we discussed previously.73 In particular,
Tan et al.72 have shown slightly lower hyperglycemia and the
resulting lower urine volume in the diabetic B2R-null mice
than in the diabetic wild-type mice during the first 11 weeks.
The difference in the severity of diabetes between the two
genotypes may have affected the development of diabetic
nephropathy.
Whether the markedly increased expression in B1R gene
that occurs in the kidney of mice lacking B2R with or without
diabetes is beneficial or deleterious is debatable.59,72,74 To
unravel the possible role of B1R in diabetes, mice lacking
both B1R and B2R (B1RB2R-null mice) were required.
However, it is impractical to make this animal model by
simply crossbreeding B1R- and B2R-null mice, because the
genomic loci coding for B1R and B2R are only 11 kb apart
in chromosome 12 and there is a very low probability of
recombination at such a small genetic distance. As no
predicted coding genes are identified between the loci for
B1R and B2R, we deleted the genomic region coding the two
receptors and were successful in generating mice lacking both
receptors.50 Another group has generated B1RB2R-null mice
by disrupting B1R using embryonic stem cells obtained from
B2R-null mice and has shown that the response to kinins, as
evaluated by contractility studies in smooth muscle cells, is
lacking, indicating that signaling via B1R and B2R mediates
most of the effects of the kinins.75
Using the B1RB2R-null animal model, we have recently
demonstrated that the pathological changes characteristic of
Akita diabetes, including nephropathy, bone mineral loss,
and neuropathy, are all enhanced in 12-month-old male
B1RB2R-null-Akita mice,76 despite similar levels of hypergly-
cemia and blood pressure. Urinary albumin excretion,
already increased 10-fold in the Akita diabetic mice
compared with wild-type mice, was increased to 17-fold in
Table 1 | Compensative expression of the remaining bradykinin receptor and the outcome on diabetic complications in kinin-
related mouse models
Induction
Expression
Reference
Genotype of diabetes Organ B1R B2R Outcome
B1R-null STZ Heart — m Reduced cardiac inflammation and fibrosis compared with STZ-treated
wild-type mice
61
B2R-null Akita Kidney m — Enhanced albuminuria and glomerulosclerosis compared with Akita
diabetic mice having both B1R and B2R
59
B2R-null STZ Kidney m — Reduced albuminuria and glomerulosclerosis compared with STZ-treated
wild-type mice
72
B1RB2R-null Akita Kidney — — Enhanced albuminuria and glomerulosclerosis compared with B2R-null
Akita diabetic mice
76
B1RB2R-null Akita Heart — — No adverse effects on cardiac function and no evidence of increased
cardiac fibrosis compared with Akita diabetic mice having both B1R and
B2R
109
TK-null STZ Kidney m m Enhanced albuminuria compared with STZ-treated wild-type mice 64
Abbreviations: Akita, Akita diabetic mice; B1R, bradykinin B1 receptor; B2R, bradykinin B2 receptor; B1RB2R, both B1R and B2R; STZ, streptozotocin;
TK, tissue kallikrein.
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the B2R-null-Akita mice and to 29-fold in the B1RB2R-null-
Akita mice, and there is a strong positive interaction between
the two mutations. The enhancement of other diabetic renal
phenotypes, including glomerulosclerosis (Figure 2), inter-
stitial fibrosis (Figure 3), and GBM thickening (Figure 4), in
Akita mice caused by the absence of both receptors is also
greater than that in Akita mice lacking only B2R. Thus, these
results establish that the increased expression of B1R induced
in the B2R-null-Akita mice has beneficial effects. In
agreement with our observations, adeno-associated virus-
mediated expression of the human tissue kallikrein has been
shown to attenuate the renal diabetic phenotypes induced by
STZ and high-fat diet as assessed by urinary albumin
excretion, histological changes, creatinine clearance, and
urinary osmolarity.77 More recently, Bodin et al.64 have
shown that mice lacking tissue kallikrein have a twofold
increase in albuminuria compared to the wild-type mice
when Type 1 diabetes is induced by STZ, despite similar
hyperglycemia and blood pressure. All these observations
indicate that KKS signaling via both B1R and B2R plays a
protective role in the development of diabetic nephropathy
and suggest that its activation could be a beneficial target for
drugs to prevent diabetic complications (Figure 1).
THE POLYMORPHISMS OF BRADYKININ RECEPTORS
Four common polymorphisms in the gene for bradykinin
receptors are described, one in the B1R promoter region
(699G/C), one in the B2R promoter region (58C/T), one
in the B2R exon 1 (þ 9/9 bp I/D), and one in the B2R exon
2 (181C/T). In the þ 9/9 genotype, the presence (þ 9)
rather than absence (9) of a 9 bp repeat sequence is
associated with decreased B2R gene transcriptional activity
and mRNA expression.78,79 In a mixed population of Type 1
and Type 2 diabetic patients, the þ 9 allele is associated with
a lower urinary albumin/creatinine ratio.80 These findings
suggest that reduced expression of the B2R gene has a
protective effect against development of microalbuminuria.
However, other association studies with this genotype show
that the þ 9/þ 9 genotype is associated with the increased
cardiovascular risk and systolic hypertension,81,82 implying a
harmful effect of the þ 9/þ 9 genotype, which is the
opposite direction against development of microalbuminuria.
Further clinical studies associated with þ 9/9 polymor-
phism on diabetic nephropathy are warranted in larger
and separated populations of Type 1 and Type 2 diabetic
patients.
ANTIFIBROTIC EFFECT OF THE KKS
Glomerulosclerosis caused by accumulation of extracellular
matrix proteins, including collagen types I, III, IV, and
fibronectin in the mesangial interstitial space, plays a critical
role in the development of diabetic nephropathy and in renal
fibrosis.83,84 Mesangial cells are potential mediators of the
glomerular damage and express both B1R and B2R,
suggesting that the KKS is implicated in the glomerulo-
sclerotic process.85–87
WT
Akita B2R-null-Akita B1RB2R-null-Akita
B2R-null B1RB2R-null
Figure 2 |Kidneys in 12-month-old male wild-type (WT), bradykinin B2 receptor (B2R)-null, bradykinin B1 and B2 receptors
(B1RB2R)-null, Akita, B2R-null-Akita, and B1RB2R-null-Akita mice stained with periodic acid–Schiff (PAS).76 Mesangial
hypercellularity, accumulation of PAS-positive extracellular matrix, and intra-arteriolar hyalinosis (insudation) in the renal glomerulus are
observed in the Akita diabetic mice. The glomerular sclerosis caused by Akita diabetes are markedly enhanced by lack of B2R and more by
lack of both receptors, even though histological changes in the non-diabetic B2R-null or B1RB2R-null mice are not remarkable at this age.
Bar¼ 100 mm.
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A number of recent studies suggest a key role of B2R
signaling in renal fibrosis in non-diabetic and diabetic
settings. B2R activation exhibits an antiproliferative effect
in mesangial cells stimulated with several growth factors.87,88
In contrast, the B2R-null mice in the unilateral ureteral
obstruction model develop significantly more tubulointer-
stitial fibrosis than wild-type mice accompanied by
decreased renal activity of plasminogen activator and matrix
WT B2R-null
B2R-null-Akita
B1RB2R-null
B1RB2R-null-AkitaAkita
Figure 3 |Gomori’s trichrome staining of renal cortex at the age of 12 months.76 The tubulointerstitial fibrosis observed in the Akita
diabetic mice are markedly enhanced by lack of bradykinin B2 receptor (B2R) and more by lack of both receptors (B1RB2R). Bar¼ 100mm.
WT, wild-type.
WT B2R-null
B2R-null-Akita
B1RB2R-null
B1RB2R-null-AkitaAkita
Figure 4 | Electron micrographs of glomeruli at the age of 12 months.76 The thickening of the glomerular basement membrane (GBM)
and foot process effacement of podocytes are observed in the Akita diabetes. The GBM thickening in the Akita diabetic mice is markedly
enhanced by lack of bradykinin B2 receptor (B2R) and more by lack of both receptors (B1RB2R), although lack of the receptors in the
absence of diabetes has little or no effect. Bar¼ 1 mm. WT, wild-type.
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metalloproteinase 2.89 Furthermore, benazepril, an ACE
inhibitor, decreases plasminogen activator inhibitor-1 ex-
pression through B2R, thereby facilitating matrix degradation
to reduce interstitial matrix deposition.90 Our observation
that the glomerulosclerosis, tubulointerstitial fibrosis, and
GBM thickening that develop in Akita diabetic mice are
enhanced by lack of B2R supports a beneficial effect of B2R
activation against diabetic renal fibrosis.59 The glomerulo-
sclerosis developing in B2R-null-Akita mice is associated with
increased megsin and nephrin expression. Megsin, a member
of the serpin family of protease inhibitors, inhibits matrix
protein degradation in the mesangium.91 Its expression is
increased to approximately two times that of wild-type in the
Akita diabetic mice and to approximately three times that of
wild-type in the B2R-null-Akita mice, which may be related
to the extent of mesangial matrix expansion.59 Expression of
nephrin, an essential component of the slit diaphragms of the
glomerulus, is increased at early stages in STZ-induced
diabetic rats,92 and nephrin expression is approximately two
times wild-type in the Akita diabetic mice and approximately
four times wild-type in B2R-null-Akita mice.59 These studies
indicate a protective effect of B2R activation in renal fibrosis.
Activation of B1R is associated with inflammatory
response. Treatment with a B1R antagonist blocks macro-
phage infiltration and B1R-null mice have lower expression
of pro-inflammatory molecules such as monocyte inflam-
matory protein 1 and interleukin-6, leading to a reduction of
renal fibrosis in the unilateral ureteral obstruction model.93,94
A B1R antagonist also reduces renal inflammation and focal
and segmental glomerulosclerosis induced by an adriamy-
cin.95 Furthermore, treatment with a B1R antagonist reduces
renal chemokine expression and macrophage accumulation,
and ameliorates the nephrotoxic serum-induced glomerulo-
nephritis.96 These studies indicate a deleterious effect of B1R
activation in renal fibrosis, despite the increase in B2R gene
expression that occurs in either B1R blockade or deletion.
We have recently shown that the glomerulosclerosis,
tubulointerstitial fibrosis, and GBM thickening that develop
in Akita diabetic mice are more enhanced by lack of both B1R
and B2R than by lack of B2R alone at the age of 12 months
(Figures 2–4).76 Expression of transforming growth factor b1,
connective tissue growth factor, and endothelin-1 is known
to be increased in diabetic nephropathy.97–99 Furthermore,
in vivo overexpression of transforming growth factor b1,
connective tissue growth factor, or endothelin-1 is associated
with the development of nephrosclerosis.100–102 The increased
expression of these fibrogenic genes is likely to contribute to
the enhanced glomerulosclerosis and fibrosis in the Akita
mice lacking both B1R and B2R. These results show that the
KKS signaling via both the B1R and B2R plays an important
role in preventing renal fibrosis in diabetic nephropathy. In
agreement with our study, bradykinin infusion prevents renal
inflammation, apoptosis, and fibrosis via inhibition of
oxidative stress and mitogen-activated protein kinase activity
in high salt-induced renal lesion in rats,103 supportive of
beneficial effect of the KKS.
In the heart, the protective effects of ACE inhibitors are
partly abolished by B2R antagonists in ischemia/reperfusion
injury104,105 and by B2R gene deletion in chronic heart
failure caused by coronary artery ligation.106 Lack of B2R
has been reported by some investigators to cause cardiac
hypertrophy and heart failure,107,108 although others have
reported that lack of B2R does not affect cardiac function
under normal physiological conditions.106 Lack of both B1R
and B2R has no adverse effects on cardiac function evaluated
by echocardiography and left-ventricular catheterization, and
the mice lacking both receptors do not exhibit any evidence
of increased fibrosis.109 On the other hand, deletion of B1R
attenuates cardiac inflammation and fibrosis in STZ-induced
diabetic mice, accompanied by an increase in B2R gene
expression.61 This apparently beneficial effect of B1R
deficiency disappears when accompanied by lack of B2R, as
Akita diabetic mice lacking both receptors do not differ in
histological changes and cardiac fibrosis compared with the
Akita mice.109 These discordant findings in Akita diabetic
mice lacking both B1R and B2R suggest the existence of
distinct tissue-specific roles of kinin receptors in the
pathogenesis of diabetic complications.
ROLE OF NITRIC OXIDE IN THE PROTECTIVE EFFECT OF THE
KKS ON DIABETIC NEPHROPATHY
Nitric oxide (NO) is synthesized enzymatically from L-
arginine by NO synthase (NOS) in almost all mammalian
cells.110,111 Three main NOS isoforms have been identified:
neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or
NOS2), and endothelial NOS (eNOS or NOS3). All isoforms
contain an N-terminal oxygenase domain and a C-terminal
reductase domain, with a recognition sequence for the Ca2þ
binding protein calmodulin located between the two
domains.112 As both nNOS and eNOS have a low affinity
for Ca2þ /calmodulin, they are activated by an elevation in
intracellular Ca2þ levels (Ca2þ -dependent isoforms). On the
other hand, as iNOS binds calmodulin with a high affinity, its
binding site is occupied at basal intracellular Ca2þ levels.
Consequently, it is not further activated by an elevation in
intracellular Ca2þ levels (Ca2þ -independent isoform).113–115
Both the B1R and B2R are coupled with Gq and Gi
proteins,49,116 and their stimulation activates phosphatidyl-
inositol-specific phospholipases, which elevates intracellular
Ca2þ levels and activates the nNOS and eNOS.49,117,118
Expression of the Ca2þ -independent isoform, iNOS, is also
increased by bradykinin via both B1R119 and B2R,120 which
is dependent on intranuclear calcium and Akt signaling.
The expression levels of iNOS are increased by lipopoly-
saccharide in wild-type mice, but this increase is diminished
in mice lacking both B1R and B2R.75 The absence of
B2R decreases the urinary excretion of stable metabolites
of NO (NO2
 and NO3
),121 and lack of both B1R and
B2R reduces fasting plasma NO2
/NO3
 concentration more
than that of B2R alone.50 These observations indicate that
both the receptors play an important role in basal NO
production.
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Reduction of NO production is associated with the
development of diabetic nephropathy. Consistent with this,
a human polymorphism in intron 4 of the NOS3 gene has
been associated with an increased risk for nephropathy
in patients with either Type 1122 or Type 2 diabetes.123
Administration of L-arginine, the substrate of the NOS,
decreases the proteinuria in STZ-induced diabetic rats.124 In
contrast, L-NAME (L-nitro-arginine methyl ester) adminis-
tration, an NOS inhibitor, aggravates the proteinuria and
histological changes that occur in the diabetic nephropathy of
Otsuka Long–Evans Tokushima Fatty rats.125 Lack of eNOS
also accelerates the severity of diabetic nephropathy in
C57BLKS/J db/db mice,126 lepr(db/db) mice,127 STZ-treated
C57BL/6 mice,128 and Akita mice.129 In rats with STZ-
induced diabetes, eNOS activity, assessed by endothelium-
dependent vasodilation and NO release from the isolated
kidney, are impaired, but administration of ACE inhibitors
restores the eNOS function.130 Expression of iNOS is
increased in the renal cortex of diabetic animals,131 but lack
of iNOS increased mesangial hypercellularity and expansion,
as well as tubulointerstitial fibrosis in mice with STZ-induced
diabetes.132 These findings suggest that the KKS exerts its
beneficial effects on diabetic nephropathy at least in part via
NO (Figure 1).
ROLE OF OXIDATIVE STRESS IN THE EFFECT OF THE KKS ON
DIABETIC NEPHROPATHY
The increased generation of reactive oxygen species (ROS) in
the kidney is associated with the progression of diabetic
nephropathy in humans and in animal models of dia-
betes.133–136 ROS, mostly generated through mitochondrial
oxidative phosphorylation, stimulate several pathways in-
volved in the pathogenesis of diabetic complications. These
include the polyol pathway flux, formation of advanced
glycation end products, expression of the receptor for
advanced glycation end products and its activating ligands,
activation of protein kinase C isoforms, and overactivity of
the hexosamine pathway.137,138 Therefore, inhibition of ROS
production has the potential of preventing ROS-induced
kidney damage in diabetes. Consistent with this, over-
expression of superoxide dismutase 1 attenuates glomerular
injury and oxidative stress in STZ-induced diabetic mice139
and in db/db mice.140 Oral administration of mitochondria-
targeted antioxidants, MitoQ, for 12 weeks decreases urinary
albumin levels and reduces renal interstitial fibrosis and
glomerular damage in Akita diabetic mice.141
Mitochondrial oxidative metabolism is reversibly inhib-
ited by NO at the level of cytochrome c oxidase, a key enzyme
in the electron transport chain.142–144 NO binds to this
enzyme and inhibits its activity reversibly, thereby negatively
regulating mitochondrial oxidative phosphorylation. Recent
studies have shown that a cAMP-dependent pathway inhibits
cytochrome c oxidase and activates the NADH-ubiquinone
oxidoreductase activity of complex I, thereby decreasing
mitochondrial respiration.145,146 Bradykinin stimulates eNOS
activity in vascular endothelial cells and increases cAMP
levels in kidney epithelial cells. Furthermore, the kinins
facilitate the synthesis of prostanoids, including prostaglan-
din E2 and I2, which elevate intracellular cAMP levels.2 In
contrast, ROS directly reduce both eNOS and prostacyclin
synthase activity.137,138 Taken together, these findings suggest
that the KKS may contribute to reducing oxidative stress via
NO and prostaglandins. In support of this possibility, we
have shown that bradykinin reduces mitochondrial super-
oxide generation in human EA.hy926 vascular endothelial
cells, an effect that is partly reversed by an NOS inhibitor.71
Protective effects of bradykinin against ROS-induced DNA
damage and senescence in bovine aorta endothelial cells are
also partly abolished by an NOS inhibitor.147 Furthermore,
bradykinin infusion via implanted minipumps or tissue
kallikrein gene delivery via tail vein injection prevents high
salt-induced renal injury in rats, being associated with
increased renal NO levels and reduced ROS generation.103,148
Cicaprost, a prostaglandin I2 analog, also attenuates the
progression of diabetic renal injury in STZ-treated rats.149
When bradykinin is administered to rats made hyperglycemic
with STZ, it also reduces their oxidative stress phenotype as
evaluated by hydrogen peroxide and malondialdehyde
levels.150 Moreover, the protective effects of ACE inhibitors
against oxidative stress are attenuated by a B2R antagonist in
STZ-treated rat assessed by serum malondialdehyde levels.
Plasma levels of thiobarbituric acid-reactive substances are
increased by 30% in B2R-null-Akita mice and further
increased by 70% in B1RB2R-null-Akita mice compared with
Akita mice alone.76 While further experimental data are
needed, these findings support a protective role of bradykinin
against ROS associated with diabetic nephropathy.
CONCLUSIONS
Many clinical studies and animal experiments have established
the protective effects of ACE inhibitors on diabetic nephrop-
athy. Accumulating evidence suggests that these beneficial
effects, which are independent of changes in blood pressure
and decreases in angiotensin II levels, are mediated in part by
the KKS. However, whether non-selective stimulation of both
B1R and B2R is more effective for the treatment of the
diabetic nephropathy than B1R- or B2R-specific stimulation
remains debatable; studies using mice lacking both B1R and
B2R indicate that non-selective stimulation is likely to have
the most therapeutic efficacy. The effects on diabetic
complications of B1R and B2R stimulation may not be the
same in all tissues. Clinical studies have given conflicting
results on the differential efficacies of ACE inhibitors in
diabetic patients with different ACE genotypes. Resolving
these uncertainties requires further studies.
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